{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:35:25Z","timestamp":1791279325805,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,1,8]],"date-time":"2015-01-08T00:00:00Z","timestamp":1420675200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1208\/s12248-014-9709-1","type":"journal-article","created":{"date-parts":[[2015,1,7]],"date-time":"2015-01-07T20:27:17Z","timestamp":1420662437000},"page":"416-426","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Population Pharmacokinetics and Exposure-Uric Acid Analyses After Single and Multiple Doses of ABT-639, a Calcium Channel Blocker, in Healthy Volunteers"],"prefix":"10.1208","volume":"17","author":[{"given":"Guohua","family":"An","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Rachel","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram","family":"Nothaft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Awni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,1,8]]},"reference":[{"issue":"4","key":"9709_CR1","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.bcp.2014.03.015","volume":"89","author":"MF Jarvis","year":"2014","unstructured":"Jarvis MF, Scott VE, McGaraughty S, Chu KL, Xu J, Niforatos W, et al. A peripherally acting, selective T-type calcium channel blocker, ABT-639, effectively reduces nociceptive and neuropathic pain in rats. Biochemical pharmacology. 2014;89(4):536\u201344. doi: 10.1016\/j.bcp.2014.03.015 .","journal-title":"Biochemical pharmacology"},{"issue":"6887","key":"9709_CR2","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nature742","volume":"417","author":"A Enomoto","year":"2002","unstructured":"Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002;417(6887):447\u201352. doi: 10.1038\/nature742 .","journal-title":"Nature"},{"issue":"2","key":"9709_CR3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/BOR.0b013e328032781a","volume":"19","author":"N Anzai","year":"2007","unstructured":"Anzai N, Kanai Y, Endou H. New insights into renal transport of urate. Curr Opin Rheumatol. 2007;19(2):151\u20137. doi: 10.1097\/BOR.0b013e328032781a .","journal-title":"Curr Opin Rheumatol"},{"issue":"9","key":"9709_CR4","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/ard.57.9.545","volume":"57","author":"F Perez-Ruiz","year":"1998","unstructured":"Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, Garcia-Erauskin G, Ruiz-Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis. 1998;57(9):545\u20139.","journal-title":"Ann Rheum Dis."},{"issue":"5","key":"9709_CR5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/21548331.1976.11706934","volume":"11","author":"WN Kelley","year":"1976","unstructured":"Kelley WN. Current therapy of gout and hyperuricemia. Hosp Pract. 1976;11(5):69\u201376.","journal-title":"Hosp Pract"},{"issue":"1","key":"9709_CR6","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0021-9258(18)56639-4","volume":"181","author":"JD Benedict","year":"1949","unstructured":"Benedict JD, Forsham PH, Stetten Jr D. The metabolism of uric acid in the normal and gouty human studied with the aid of isotopic uric acid. J Biol Chem. 1949;181(1):183\u201393.","journal-title":"J Biol Chem"},{"key":"9709_CR7","doi-asserted-by":"crossref","unstructured":"Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007\u20132008. Arthritis Rheum. 63(10):3136\u201341. doi: 10.1002\/art.30520 .","DOI":"10.1002\/art.30520"},{"issue":"Suppl 1","key":"9709_CR8","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/ar1909","volume":"8","author":"R Terkeltaub","year":"2006","unstructured":"Terkeltaub R, Bushinsky DA, Becker MA. Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Res Ther. 2006;8 Suppl 1:S4. doi: 10.1186\/ar1909 .","journal-title":"Arthritis Res Ther"},{"issue":"9711","key":"9709_CR9","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0140-6736(09)60883-7","volume":"375","author":"P Richette","year":"2010","unstructured":"Richette P, Bardin T. Gout. Lancet. 2010;375(9711):318\u201328. doi: 10.1016\/S0140-6736(09)60883-7 .","journal-title":"Lancet"},{"issue":"10","key":"9709_CR10","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","volume":"65","author":"W Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312\u201324. doi: 10.1136\/ard.2006.055269 .","journal-title":"Ann Rheum Dis"},{"issue":"23","key":"9709_CR11","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher Jr HR, Wortmann RL, MacDonald PA, Eustace D, Palo WA. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450\u201361. doi: 10.1056\/NEJMoa050373 .","journal-title":"N Engl J Med"},{"issue":"13","key":"9709_CR12","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.2165\/00003495-200868130-00006","volume":"68","author":"PI Hair","year":"2008","unstructured":"Hair PI, McCormack PL, Keating GM. Febuxostat. Drugs. 2008;68(13):1865\u201374.","journal-title":"Drugs"},{"issue":"4","key":"9709_CR13","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/ard.16.4.425","volume":"16","author":"MA Ogryzlo","year":"1957","unstructured":"Ogryzlo MA, Harrison J. Evaluation of uricosuric agents in chronic gout. Ann Rheum Dis. 1957;16(4):425\u201337.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"9709_CR14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","volume":"76","author":"KR Hande","year":"1984","unstructured":"Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76(1):47\u201356.","journal-title":"Am J Med"},{"issue":"1","key":"9709_CR15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11926-001-0048-8","volume":"3","author":"AG Fam","year":"2001","unstructured":"Fam AG. Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient. Curr Rheumatol Rep. 2001;3(1):29\u201335.","journal-title":"Curr Rheumatol Rep"},{"issue":"7","key":"9709_CR16","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1056\/NEJM199602153340707","volume":"334","author":"BT Emmerson","year":"1996","unstructured":"Emmerson BT. The management of gout. N Engl J Med. 1996;334(7):445\u201351. doi: 10.1056\/NEJM199602153340707 .","journal-title":"N Engl J Med"},{"issue":"3","key":"9709_CR17","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s11926-996-0044-0","volume":"7","author":"N Anzai","year":"2005","unstructured":"Anzai N, Enomoto A, Endou H. Renal urate handling: clinical relevance of recent advances. Curr Rheumatol Rep. 2005;7(3):227\u201334.","journal-title":"Curr Rheumatol Rep"}],"updated-by":[{"DOI":"10.1208\/s12248-015-9725-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2015,2,13]],"date-time":"2015-02-13T00:00:00Z","timestamp":1423785600000}}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-014-9709-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12248-014-9709-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-014-9709-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T08:53:49Z","timestamp":1650963229000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12248-014-9709-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,8]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["9709"],"URL":"https:\/\/doi.org\/10.1208\/s12248-014-9709-1","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,8]]}}}